HC Wainwright Cuts Vor Biopharma (NASDAQ:VOR) Price Target to $32.00

Vor Biopharma (NASDAQ:VOR) had its price objective lowered by HC Wainwright from $55.00 to $32.00 in a report published on Friday,Benzinga reports. The brokerage currently has a buy rating on the stock.

A number of other equities research analysts also recently weighed in on the company. Stifel Nicolaus raised Vor Biopharma from a “hold” rating to a “buy” rating and set a $55.00 target price on the stock in a report on Wednesday, September 24th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Vor Biopharma in a research report on Wednesday, October 8th. Zacks Research raised shares of Vor Biopharma from a “strong sell” rating to a “hold” rating in a report on Tuesday, November 11th. Baird R W upgraded shares of Vor Biopharma from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, October 15th. Finally, Robert W. Baird raised shares of Vor Biopharma from a “neutral” rating to an “outperform” rating and lifted their price target for the company from $20.00 to $64.00 in a report on Wednesday, October 15th. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $73.17.

Vor Biopharma Price Performance

Shares of NASDAQ VOR opened at $10.01 on Friday. The firm has a fifty day moving average of $28.94. The firm has a market cap of $68.57 million, a PE ratio of -0.03 and a beta of 2.02. Vor Biopharma has a fifty-two week low of $2.62 and a fifty-two week high of $65.80.

Vor Biopharma (NASDAQ:VOR) last issued its quarterly earnings results on Thursday, November 13th. The company reported ($3.33) EPS for the quarter, missing analysts’ consensus estimates of ($3.06) by ($0.27).

Insiders Place Their Bets

In other news, major shareholder Reprogrammed Interchange Llc sold 11,616 shares of the company’s stock in a transaction dated Monday, October 20th. The shares were sold at an average price of $30.05, for a total transaction of $349,060.80. Following the transaction, the insider owned 1,167,109 shares in the company, valued at approximately $35,071,625.45. This represents a 0.99% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Ra Capital Management, L.P. sold 24,579 shares of the firm’s stock in a transaction that occurred on Thursday, October 30th. The shares were sold at an average price of $25.12, for a total value of $617,424.48. Following the completion of the sale, the director directly owned 779,652 shares of the company’s stock, valued at $19,584,858.24. This trade represents a 3.06% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 2,431,718 shares of company stock valued at $62,090,254 over the last 90 days. Corporate insiders own 0.45% of the company’s stock.

Hedge Funds Weigh In On Vor Biopharma

Several large investors have recently bought and sold shares of the stock. OMERS ADMINISTRATION Corp bought a new stake in shares of Vor Biopharma in the 1st quarter worth $100,000. Goldman Sachs Group Inc. lifted its position in shares of Vor Biopharma by 218.2% during the first quarter. Goldman Sachs Group Inc. now owns 84,945 shares of the company’s stock valued at $61,000 after purchasing an additional 58,247 shares in the last quarter. Jane Street Group LLC purchased a new position in Vor Biopharma during the first quarter worth about $140,000. XTX Topco Ltd purchased a new position in Vor Biopharma during the second quarter worth about $66,000. Finally, Ariose Capital Management Ltd bought a new stake in Vor Biopharma in the 3rd quarter worth about $5,368,000. 97.29% of the stock is currently owned by institutional investors.

About Vor Biopharma

Vor Biopharma, Inc, a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company’s VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells.